UW Comprehensive Cancer Center Support

华盛顿大学综合癌症中心支持

• 批准号: 8765061
• 负责人: GEORGE WILDING
• 金额: $ 3.74万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-30 至 2015-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8765061
• 关键词: Award; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Patient; Caring; Clinic; Clinical; Clinical Research; Clinical Trials Design; Commit; Comprehensive Cancer Center; Evaluation; Faculty; Funding; Future; Goals; Growth; Housing; Institutes; Instruction; International; Malignant Neoplasms; McArdle Laboratory for Cancer Research; Medical Research; NCI Center for Cancer Research; Process; Recording of previous events; Recruitment Activity; Research; Research Institute; Schools; Sum; Translating; Universities; Wisconsin; anticancer research; clinical care; member; research facility; square foot

DESCRIPTION (provided by applicant): The University of Wisconsin Carbone Cancer Center (UWCCC) is comprised of 216 research members from 45 departments and 11 schools of the University of Wisconsin Madison. UW-Madison has a long and rich history as an international leader in basic, translational and clinical cancer research reflected in its history of two NCI-designated and -funded cancer research centers founded by Dr. Harold Rusch on the UW-Madison campus. The McArdle Laboratory for Cancer Research was founded in 1940 and received its initial NCI funding in 1946. UWCCC has received continuous NCI funding since 1973 when it was awarded NCI funding as one of the first six comprehensive cancer centers. After a coordinated process during the late 1990's, both centers were consolidated under UWCCC in 2001 when the first NCI Cancer Center Support Grant representing the consolidated centers was awarded. The consolidation of the two centers has generated tremendous enthusiasm and growth for cancer research on the UW-Madison campus over the past ten years. This has resulted in a Center greater than the sum of the two parts existing before the consolidation. With the completion of the Wisconsin Institutes of Medical Research (WIMR) Tower 1 in 2008 and with Tower 2 completion projected for 2013, UWCCC will have approximately 350,000 sq ft of contiguous space dedicated to cancer clinical care and research, a nearly three-fold increase over the past ten years. In addition, the new Wisconsin Institutes of Discovery (WID), a $200 million UW-Madison central campus research facility that also includes the privately-operated Morgridge Institute for Research (MIR), opened in 2011. WID/MIR will house 10 focused research teams of four or more faculty each. Five of these teams are led by UWCCC members representing a strong cancer research presence in the WID/MIR. Three quarters of the faculty in WID will be new recruits to UW-Madison. The three future highest goals of UWCCC are unchanged from the current goals: 1) to conduct the highest quality research into the origins and control of cancer; 2) to translate these research findings to evaluation in the clinic through well-designed clinical trials with corresponding biologic endpoint whenever possible; and 3) to provide the best care possible to all cancer patients by carefully integrating high quality, cutting-edge care with clinical research in a compassionate and individualized manner. UWCCC has $30.7 million in NCI funding (direct) and a total of $83.7 million cancer focused research funding.

描述（由申请人提供）：威斯康星大学卡本癌症​​中心 (UWCCC) 由来自威斯康星大学麦迪逊分校 45 个系和 11 个学院的 216 名研究人员组成。威斯康星大学麦迪逊分校作为基础、转化和临床癌症研究领域的国际领导者，拥有悠久而丰富的历史，这体现在其由 Harold Rusch 博士在威斯康星大学麦迪逊分校校园内创建的两个 NCI 指定和资助的癌症研究中心的历史上。麦卡德尔癌症研究实验室成立于 1940 年，并于 1946 年首次获得 NCI 资助。UWCCC 自 1973 年作为首批六家综合癌症中心之一获得 NCI 资助以来，一直持续获得 NCI 资助。经过 1990 年代末的协调过程，两个中心于 2001 年合并到 UWCCC 之下，当时颁发了代表合并中心的第一笔 NCI 癌症中心支持拨款。过去十年，两个中心的合并为威斯康辛大学麦迪逊分校校园的癌症研究带来了巨大的热情和增长。这导致中心比合并前现有的两个部分的总和还要大。随着威斯康星医学研究院 (WIMR) 1 号塔楼于 2008 年竣工，2 号塔楼预计于 2013 年竣工，UWCCC 将拥有约 350,000 平方英尺的连续空间专门用于癌症临床护理和研究，在过去十年中增加了近三倍。此外，新的威斯康星州探索学院 (WID) 是一座耗资 2 亿美元的威斯康星大学麦迪逊分校中心校园研究设施，其中还包括私人运营的莫格里奇研究所 (MIR)，于 2011 年开业。WID/MIR 将容纳 10 个重点研究团队，每个团队由 4 名或更多教职人员组成。其中五个团队由 UWCCC 成员领导，代表着 WID/MIR 强大的癌症研究实力。 WID 四分之三的教职员工将是威斯康辛大学麦迪逊分校的新员工。 UWCCC未来的三个最高目标与当前目标保持不变：1）对癌症的起源和控制进行最高质量的研究； 2）尽可能通过精心设计的具有相应生物学终点的临床试验将这些研究结果转化为临床评估； 3) 以富有同情心和个性化的方式仔细地将高质量、尖端的护理与临床研究结合起来，为所有癌症患者提供最好的护理。 UWCCC 拥有 3070 万美元的 NCI 资金（直接）和总计 8370 万美元的癌症重点研究资金。